Drugs / METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01812369 Comparator | Feb 2013 → Sep 2023 | urinary bladder cancer | University Hospital, Rouen | Completed | Missed primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01812369 ↗ |